

OUR CONTRIBUTIONS TO THE FIGHT AGAINST COVID-19

EMD
SERONO

MILLIPORE
SIGMA

EMD
ELECTRONICS

We are dedicated to serving patients, scientists and healthcare providers around the world – now more than ever.

PREVENTION

In 2020, we offered a research grant of up to

€ **500,000**

per year for three consecutive years to external research teams working on pandemic preparedness projects.

Since October 2020, we have been partnering with the Californian company **Mammoth Biosciences** for the development, scale-up and commercial production of a CRISPR-based Covid-19 diagnostic test.

In February 2021, we announced the expansion of our strategic partnership with BioNTech and will increase our supply volume of lipids needed for the **Pfizer-BioNTech vaccine**.

In March 2020, we started to deploy a **testing program** (rapid antigen tests and real-time PCR tests) for its employees at around 20 sites in eight countries. By **providing the data** to the international scientific community, we are contributing to advance the understanding of the Covid-19 disease.


TREATMENT

We are a member of the **CARE** (Corona Accelerated R&D in Europe) consortium aimed at advancing research and future treatments. Studies are also underway to investigate whether existing therapies can be used to treat Covid-19.

As a result of the acquisitions of **AmpTec** and **Exelead** in 2021 and 2022, respectively, we are strengthening our capacity for developing and manufacturing vaccines and treatments based on messenger ribonucleic acid (mRNA) technology.

Our Life Science business sector participates in the **MIT Pandemic Response CoLab**, which helps individuals and groups work together to solve practical problems created by the Covid-19 pandemic by leveraging an open online collaboration platform.

Since 2019, we have been a member of the **Transvac program** to advance vaccine development and manufacturing in Europe. It promotes close cooperation between governments, research institutions, industry, and other partners.




PRODUCTION

In December 2020, our company announced the **broadening of its manufacturing footprint** with a combined **€ 40 million** investment at its Life Science production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire, USA. These sites supply critical products to customers developing lifesaving therapies, including Covid-19 vaccines.

In March 2021, we announced to accelerate our European expansion plans for **single-use products** which are critical to manufacturing vaccines and lifesaving therapies. A **€ 25 million** investment in Molsheim, France, will create **350 new jobs**. In addition, **capacity expansion activities** are underway at our single-use production site in **Wuxi, China**.

In December 2021, we announced the collaboration with **"Innovative Biotech" in Nigeria** to support the West African pandemic readiness program by accelerating self-sufficient vaccine development and manufacturing.

Since the start of the pandemic, we maintained the **production and supply chains** of our Healthcare business sector across the globe and supplied more than **90 million patients** worldwide with their (non-Covid-19-related) medication.



GOOD TO KNOW

Our **liquid crystal technology** is used in X-ray imaging technologies, ventilators and monitors to keep track of the vital signs of patients in intensive care units.

Our **electronic materials** help people all over the world to stay in contact and **are also used in the medical equipment** that is needed to detect and fight Covid-19.

FURTHERMORE

Our employees and the company donated around **€ 140,000** to **"Save the Children"** to support educational projects for children and their families during the Covid-19 pandemic.

In more than **40 countries** we organized multiple donation efforts, adding up to cash and goods worth **millions of euros**, including **FFP2 masks**, 3D-printed face shields and disinfectant, both manufactured in-house.

The **Foundation** financed exclusively by the private funds of the family of the company owners joined the company in the fight against Covid-19: Since 2020, it has donated a total of **€ 4.2 million to 26 charitable projects**, ranging from the distribution of food packages to funding the construction of a hospital.

WE HAVE SUPPORTED OR HELPED DEVELOP ...

> **80** vaccine projects > **35** testing solutions > **50** monoclonal antibodies, plasma products and antiviral drugs

EMPLOYEE HEALTH & SAFETY

The **Corporate Crisis Management Team** provides global guidance on hygiene measures, travel and meeting restrictions adaptable to local needs.

A holistic **hygiene and physical distancing concept** with comprehensive measures was put in place for our people on site including special arrangements for employees with preexisting health conditions or childcare obligations.

We provide **psychological counseling** via Employee Assistance Programs for our employees in all countries, often 24/7.

We are offering several **free-of-charge training elements** to support our employees in managing the Covid-19 crisis.

We produce **FFP2 protective face masks** at our Healthcare manufacturing site in Nantong, China, to deliver fully certified masks to our employees in Europe and Asia.

We are supporting our employees and their local communities in **heavily affected countries**. In India, for example, we provided **€ 2 million for vaccinations and medical equipment**.

In October 2021, we launched an **international social media campaign** about the **impact of the pandemic on employees** and its effects on well-being and work life.

During the two-month **lockdown in Shanghai** in spring 2022, employees maintained essential business operations to supply our customers: At two Electronics sites, around 40 colleagues were unable to go home and stayed overnight in factories. Our local crisis teams **helped with food procurement and offered extensive psychological support** during this time.

EARLY MILESTONES

In 2019, we awarded **€ 1 million** to Pardis Sabeti and James Crowe, the winners of the **Future Insight Prize**, for outstanding research on the topic of **pandemic preparedness**.

In 2020, we partnered with the **Jenner Institute** of the University of Oxford to develop a manufacturing process for a vaccine, which has been approved for emergency use in multiple countries. We also partnered with **Baylor College of Medicine** in Houston, Texas, to develop manufacturing platforms for two vaccines, which are in clinical trials.

